Open Access

Role of apoptosis in pathogenesis and treatment of bone-related diseases

  • Samaneh Mollazadeh1,
  • Bibi Sedigheh Fazly Bazzaz2 and
  • Mohammad Amin Kerachian3, 4Email author
Journal of Orthopaedic Surgery and Research201510:15

https://doi.org/10.1186/s13018-015-0152-5

Received: 3 October 2014

Accepted: 2 January 2015

Published: 28 January 2015

Abstract

In this article, bone cells and their intercellular communications have been reviewed. Gap junctions and hemichannels are the main routes of interactions in bone tissue. They play a substantial role in survival and cell death, since pro-apoptotic signals can propagate through them. Different adhesion molecules are required for apoptosis, particularly caspase family as well as noncaspase proteases. The disruption outcome of apoptosis could result in bone-related diseases such as osteonecrosis. Anti-apoptotic strategies include inhibition of caspase, poly [ADP-ribose] polymerase (PARP), and Bcl-2 proteins as well as induction of the PKB/Akt pathway and inhibitors of apoptosis (IAP) family of proteins. Thus, understanding the mechanism of apoptosis gives detailed insights of anti-apoptotic molecular targets. Based on these targets, different treatments were designed and produced such as estrogen replacement therapy, administration of different bisphosphonates, raloxifene, calcitonin, sodium fluoride, calcium, and vitamin D. As a result, new applicable drugs for treatment of related bone problems can be proposed for clinical approach especially in the early stage of diseases.

Keywords

ApoptosisBone disorderCell-cell interactionsGap junction

Introduction

Bone as a mineralized and dynamic tissue supports and protects the rest of body [1,2]. Different kinds of stimuli affect the modeling and remodeling process in the bone tissue [3,4]. These include endocrine, paracrine, and autocrine factors, direct cell to cell communication through gap junctions [5], with greater frequency of connexin 43 (C×43), connexin 45 (C×45), and connexin 46 (C×46) [3] and cell-to-matrix communication through hemichannels [6]. Besides, coordinated interaction between bone cells plays a considerable role in bone remodeling [7]. The main bone cells are osteoblasts, osteocytes, and osteoclasts. Osteoblasts, which are responsible for maintaining skeletal architecture, originate from pluripotent mesenchymal cells [2,8]. The most abundant bone cells are osteocytes, differentiated osteoblasts, lying in the lacunar space enclosed by the bone matrix [9,10]. Osteocytes compose lacunar-canalicular network by their cytoplasmic dendrites that connect them to each other and to cells on the bone surface, important for intracellular and extracellular communication (Figure 1) [11,12]. The third main class of bone cells is osteoclast. Osteoclasts are giant multinucleated cells with abundant mitochondria, multitudinous lysosomes, and free ribosomes [2,13]. These cells differentiated from hematopoietic stem cells and are responsible for bone resorption [14,15], that is dissolving and breaking down mineral and organic substrates [16].
Figure 1

Gap junction channels (GJC) and hemichannel (HC) in skeleton. As it is presented in this schematic presentation, HC composing connexon placing on the body of osteocytes and osteoblasts respond to different signals which then control the transmission of different factors among are PGE2, ATP, and PNS. Also, GJC forming by contacting two HC from adjacent cells present among osteoblasts, between dendritic process of osteocytes, osteocyte-osteoblast as well as osteocyte-osteoclast. Various mechanical, hormonal, and biochemical factors affect the expression and function of GJC. Altogether, cross-talks among bone cells through these junctions regulate bone biology.

This article provides an overview of what is currently known about cell death in the osteoclast and osteoblast lineages and how the death of these cells may be related to clinically important bone diseases.

Apoptosis and cell signaling

Cell death occurs under physiological and pathological conditions and mediates through three pathways as follows: apoptosis, autophagic cell death, and necrosis. In contrast to necrosis (murdered cells), in apoptosis (commit suicide) and autophagy process, cytoplasmic membranes are maintained and cell body is completely removed without any inflammation. However, if phagocytosis of the cell does not occur at the final stage of apoptosis or autophagic process, the cells are removed through secondary necrosis [12]. Apoptosis was first described by Kerr and colleagues in 1972 [17] as a physiological situation characterized by distinguishable morphological features such as nuclear changes (nuclear chromatin condensation and nuclear fragmentation), cell contraction, and losing attachment with adjacent cells. Also, this process can be governed by regulatory factors within the cell, and it can be induced or inhibited by external factors [1,18]. Additionally, apoptosis is a regulatory program which has a noteworthy role during development and growth and maintaining the skeleton [19,20]. Although insufficient apoptosis occurs in cancer or autoimmunity status, in degenerative diseases, immunodeficiency, and infertility, cell death is accelerated [21].

Apoptotic process triggers by different pathways: one is through mitochondrial (intrinsic pathway) and the other is established by ligand activation via death receptors (extrinsic pathway) (Figure 2) [20,22,23]. These receptors, belonging to tumor necrosis factor (TNF) receptor superfamily, include CD95 (Fas), TNF-related apoptosis-inducing ligand (TRAIL) R-1 and R-2, and TNF-R1 [21]. It has been postulated that, TRAIL as well as Fas pathways mediate osteoclast apoptosis in human [23]. The bone is to a certain extent inactive at the cellular level; thus, cell death in this tissue is a critical issue in its physiology or pathology [1]. During aging, the number of apoptotic osteoblasts and osteocytes increases, which ends up to falling in osteoblast number and bone formation [24].
Figure 2

Two apoptotic pathways are demonstrated. Extrinsic pathway which is triggered through death receptors and intrinsic one which is caused by mitochondrial alterations. In the extrinsic pathway, binding death ligands to their receptors mainly CD95 (Fas), TNFR1, and TRAIL triggers death signal through Fas-associated death domain (FADD) which then activates caspase-8. In the intrinsic pathway, cytochrome C (Cyt-C) is released from the mitochondria and form apoptosome complex after attaching to apoptotic protease activating factor-1 (Apaf-1) followed by activating caspase-9. The activated caspase-8 and 9 (initiator) activate the effector caspases 3, 6, and 7 which then results in cell death characterized by obvious morphological and biochemical alterations. Furthermore, cell death depends on amounts of various members of Bcl2 family. For more information, read the text.

The main adhesion molecules required for bone cell development and apoptosis are integrins, especially αvβ3 (vibronectin receptor integrin) and α2β1 (collagen-binding integrin), selectins, caspase, and a family of transmembrane proteins containing a disintegrin and metalloprotease domain (ADAMS) [13].

Caspase activity plays a key role in osteoblast apoptosis; however, it may be also important in osteogenesis [25]. Caspase-activated DNAse (CAD), which breaks DNA down to fragments, is activated in the early phase of apoptosis. Procaspase-8 and 9 are activated by death receptor or through release of some molecules such as cytochrome C from the mitochondria. Effector caspases (caspase-3, −6, and −7) are activated after cleavage of procaspase-8 and 9. As a final point, effector caspases cleave their targets in the nucleus and cytoplasm. The release of protein-activated caspase through the mitochondria is governed by Bcl-2 family [22]. Bad, Bax, and Bid are the apoptotic members of this family while Bcl-2 and Bcl-xL are considered as anti-apoptotic components [20]. Besides, other pro-apoptotic proteins such as apoptosis-inducing factor (AIF), Smac/DIABLO, and Omi/HtrA2 are released after initial apoptotic stimuli [21]. Osteoblast apoptosis is known as a complex process which is affected by various factors including Bcl-2 family proteins, extracellular signal-regulated kinase (ERK), mitogen-activated protein kinases (MAPK), APJ/PI3-K/Akt, Janus kinase 2 (JAK2), Fas [26,27], bone morphogenetic protein (BMP), and bone matrix protein [25]. Apoptosis in osteoblasts can be triggered via physiological or pathological factors [26], i.e., osteoblasts apoptosis can be induced by oxidized lipids which then inhibit osteoblast differentiation through reactive oxygen species (ROS)-independent mechanisms. It has been shown that functional forkhead box O3 (FoxO3) in osteoblast not only reduces oxidative stress and osteoblast apoptosis but also increases osteoblasts number, bone formation rate, and mass [24]. Furthermore, matrix proteins, such as fibronectin and osteopontin are involved in osteoblast apoptosis and survival [28]. The balance between the birth of osteoblast from mesenchymal processors and the apoptotic death would determine the number of cells [18].

Another important factor in apoptosis is p53 (tumor suppressor protein) which is activated through ROS, DNA damage, and other harmful stimuli such as oncogene activation and hypoxia. Extended p53 activation leads to increased apoptosis through raised ROS levels. Also, p53 modulates ROS production through various mechanisms such as enhanced p66Shc protein which affects generation of ROS in mitochondria along with converting the oxidative signals into apoptosis. During aging, phosphorylated forms of p53 and p66Shc are increased in the bone as well as enhanced levels of ROS and apoptotic osteoblasts [24].

Although the life span of human osteoclasts is around 2 weeks, this time for osteoblasts is 3 months. Investigators have shown that growth factors and cytokines that affect osteoclast and osteoblast development can also stimulate their apoptosis [13].

Likewise, apoptosis in osteocytes increases with age and is related with decreased levels of receptor activator of nuclear factor kappa-B (NF-kβ) ligand (RANKL) and sclerostin protein in the bone. Accordingly, oxidative stress or other mechanisms related to aging can affect bone remodeling [24].

Since osteocytes are embedded in mineralized matrix, scavengers cannot reach them and osteocyte death causes cell disruption. Release of immunostimulatory molecules from lacunae activates macrophages producing proinflammatory cytokines such as TNF-α, interleukin (IL)-6, and IL-1. Current cytokines trigger bone loss. Besides, RANKL expression is induced via IL-6 as well as IL-1. It has been shown that apoptotic osteocytes are characterized by degraded DNA in lacunae and increased expression of specific factors, promoting osteoclastogenesis. Besides, bone resorption caused by osteocytes death is via release of intracellular content of dead osteocytes through canicular system [12]. Probably, matrix metalloproteinase (MMP)-resistant mutant of type I collagen induces osteocyte apoptosis. The osteocyte network suppresses bone formation under physiological conditions. Interestingly, osteocyte apoptosis is induced by strain causing microdamage in the bone [18]. Overall, microcracks and fatigue as well as pro-apoptotic factors trigger osteocyte death, which could activate osteoclasts. In contrast, there are some factors not only causing osteocyte survival but also osteoblast activation [10].

Altogether, apoptosis as a part of a normal physiological process could be dysregulated and causes apoptotic-related bone diseases.

Apoptosic-related bone diseases

Extensive cell communication network made by osteocytes could detect mechanical loadings and microdamage to the bone tissue. Drugs and bone active hormones control the bone strength and integrity of this network through the regulation of osteocyte cell death [29]. Irregularities in apoptosis account for different diseases which result from either extensive or inadequate cell death [20]. Accordingly, interruption in bone remodeling, characterized by survival and apoptosis of bone tissue leads to diseases such as osteoporosis or malignant osteolysis [23].

In osteoarthrosis, hyperparathyroidism, and Paget’s disease of bone (PDB), apoptosis in osteoclasts is evident [1]. However, it has been revealed that in the osteoporotic bone, the rate of apoptosis is lower than that in the osteoarthritic bone [19]. Other bone problems mediated by osteoclast apoptosis are post-menopausal osteoporosis and rheumatoid arthritis (RA). It was revealed that Bcl-xL, an anti-apoptotic protein of the Bcl-2 family, is overexpressed in the inflamed joints of TNF transgenic mice and RA patients [30].

Osteoblast apoptosis brings about different bone problems especially osteoporosis [26]. Apoptosis in osteoblast lineage has been reported in the proximal femur particularly in the femoral head from elderly than young subjects [1]. Weinstein and his colleagues showed that glucocorticoid-induced osteonecrosis of the femoral head is not necrosis; instead, prominent apoptosis of cancellous lining cells and osteocytes occurs. Osteocyte apoptosis induced by glucocorticoid could disrupt the mechanosensory function of the osteocyte network and thus triggers a sequence of events leading to disintegration of the femoral head [31]. However, many factors are involved in etiopathogenesis of osteonecrosis such as alcohol or glucocorticoids [32,33]. We studied the role of glucocorticoids in the development of osteonecrosis [34]. Glucocorticoids induce osteonecrosis through various mechanisms, most importantly through its direct effect on bone and vascular cells causing osteoblast-osteocyte apoptosis and vascular bedding damage [35]. The effects of glucocorticoid on osteocytes lead to reduction in fluid transportation in lacunar-canalicular system, vascularity, and strength of the bone [36]. So, glucocorticoids are considered as great inhibitors of bone formation since they stimulate osteoblast apoptosis [24,35]. The mechanism by which glucocorticoids stimulate apoptosis is reported to depend on interactions between glucocorticoid receptors, dimerization of receptors and regulation of gene expression. Dexametasone (Dex), as a glucocorticoid, may increase the expression of pro-apoptotic genes inducing apoptosis [37]. Furthermore, aminobisphosphonates used for the treatment of osteoporosis and other disorders of bone resorption may induce apoptosis in osteoblasts and inhibit their differentiation [38]. Increased expression of inducible nitric oxide synthase (iNOS) in osteonecrotic patients elevates toxic levels of NO, which have deleterious effects on osteoblastogenesis followed by high amounts of apoptotic cells [32].

It was reported that increased apoptosis in myeloma bone microenvironment accounts for impaired new bone formation due to high amounts of cytokine as well as physical interaction among osteoblasts and malignant plasma cells [39]. Studies also have shown that pathogenesis of osteosarcoma is related to abnormal function of p53 and the retinoblastoma gene [1]. Altogether, osteoblast apoptosis which is to some extent influenced by lack of sex steroid, excess of glucocorticoids, or aging results in bone loss [19].

Anti-apoptotic factors in bone loss

Anti-apoptotic procedures in the case of pathologically increased cell death are as follows: inhibition of caspase, poly [ADP-ribose] polymerase (PARP), and Bcl-2 proteins as well as induction of the PKB/Akt pathway and the inhibitor of apoptosis (IAP) family of proteins [20]. It was shown that overexpression of Bcl-2 prevents apoptosis through cytochrome C release inhibition [40]. Activation of PKB/Akt by kinases like phosphoinoside-dependent kinase 1 (PDK1) creates protection against apoptosis [41]. Also, the anti-apoptotic effect of IAP occurs by suppressing enzymatic function of caspases [42]. Various apoptotic-related diseases can be treated by inhibition of caspase activities followed by a decrease in apoptosis and organ function refining. It was reported that Casp3Inh (Z-DEVD-FMK) inhibits caspase-3 activity which could affect bone mineral density (BMD) by upregulation of transforming growth factor (TGF-β)/Smad2 signaling pathway in bone marrow stromal stem cells (BMSSCs). Furthermore, it was proved that Z-DEVD-FMK prevents osteogenic differentiation in human BMSSCs through inhibition of caspase-3 activity. Therefore, caspase-3 plays a considerable role in bone development and metabolism [25]. Besides, survival signals can be generated by intracellular kinase cascade including states, ERK, Akt, and phosphathidyl inositol-3-kinase (PI3K). Along with this, focal adhesion kinase (FAK) activation activates PI3K and/or the MAP kinase cascade, which prevents apoptosis [43]. PI3K, which is activated through different extracellular signals such as insulin and insulin-like growth factor I (IGF-I), significantly is involved in several anti-apoptotic pathways as well as enhancing proliferation by Akt/PKB. Phosphatase and tensin homologue (PTEN) as a tumor-suppressor gene prevents the activity of PI3K. Lack of PTEN increases bone mass through promoting the number of osteoblasts probably via the deceleration of apoptosis [26]. Recent studies suggest that Wnt/b-catenin activates anti-apoptotic signaling pathways that primarily act through Src/ERK and PIK3/Akt [18]. Activation of NF-kB is considered as an inhibitor of apoptosis induced by death receptor [30]. TGF-β, IGF-I, fibroblast growth factor 2 (FGF-2), and IL-6 have anti-apoptotic effects on cultured osteoblastic cells. Moreover, MMP-resistant mutant of type I collagen has the same effect on these cells [18]. IL-1 is considered as an anti-apoptotic factor which its lack results in increase osteoclast apoptosis by diminishing prostaglandins concentration or other anti-apoptotic factors. Osteoclasts apoptosis can be prevented by 1,25 (OH)2 vitamin D3 and parathyroid hormone (PTH) probably through RANKL stimulation or reduction in osteoprotegerin (OPG) expression. It was suggested that PI3K/Akt signaling pathway has a positive regulatory effect on osteoclast formation. Macrophage colony-stimulating factor (M-CSF) and RANKL stimulate the expression of anti-apoptotic gene Bcl-2 and Bcl-xL and x-linked inhibitor of apoptosis protein (XIAP). Besides, RANKL-activated NF-kB is required for osteoclast survival [43]. NF-kB, which has an anti-apoptotic effect on some cell types including osteoclasts, is activated by binding TNF to its receptor [24]. In contrast, strontium ranelate enhances osteoclast apoptosis through a calcium-sensing receptor (CaR)-dependent mechanism [44]. OPG, a TRAIL receptor, plays a key role in the inhibition of apoptosis induced by TRAIL [30]. Similar to M-CSF, IL-1, TNF-α, and IL-6, there are other cytokines which inhibit osteoclast apoptosis. Inducer factors of bone resorption inhibit osteoclast apoptosis, while their suppression stimulates the apoptosis. Estrogen, 17f-oestradiol (E2), increases the number of apoptotic osteoclasts; however, the effect of E2 on osteoclast could be reversed by a pan-specific anti-TGF antibody as well as estrogen agonist/antagonist tamoxifen. Likewise, integrins such as αvβ3 integrin has a similar effect on the bone which increases osteoclast apoptosis. Other findings suggest that interactions between osteoclast matrix regulate osteoclast apoptosis [1]. The same cytokines and growth factors affect not only osteoblast and osteoclast development but also their apoptosis. In this case, IL-6 blocks apoptosis of osteoblastic cells of animal and human as well as osteoclasts and their processors. Also, it has been reported that TGF-β has an anti-apoptotic effect on osteoblast while it could increase osteoclast apoptosis [13]. Several endogenous stimuli (systemic, local, or mechanical) have anti-apoptotic effects on bone cells through C×43 or cell-to-cell communication. Similarly, anabolic and anti-catabolic inducers have anti-apoptotic effects on bone-forming cells such as the anabolic effects of PTH, activators of the Wnt signaling pathway, and mechanical stimuli [45].

Anti-apoptotic drugs and treatment of bone loss

Bisphosphonates are anti-catabolic drugs administering in disorders including malignant osteolysis, osteoporosis, and PDB [30]. It was reported that bisphosphonate drug (alendronate) needs C×43 hemichannels to inhibit apoptosis in osteoblast through activation of src-ERK [38,45,46]. It is supposed that alendronate enters to the cell after inducing C×43 opening. Alendronate causes closure of C×43 hemichannels by phosphorylation of the C-terminal cytoplasmic domain after interaction with Src kinase, the upstream activator of ERK [47]. Besides, the current drug has the same effect on osteocytes via cytoplasmic ERK activation and influencing the canonical nuclear translocation pathway signaling cascade [3,48]. Likewise, alendronate has a prevailing effect on inhibition of osteoclastic resorption in glucocorticoid-induced bone loss [45]. Since bisphosphonate increases osteoclast apoptosis in human and rodents, it is considered as a potential treatment in PDB and post-menopausal osteoporosis [1]. As the mechanism of action of bisphosphonates in osteoblasts and osteocytes depends on C×43 hemichannels, the current compounds are considered as an anti-apoptotic pharmacological target [38,45,46]. Because sex steroid paucity as well as glucocorticoids induce bone apoptosis, protection against them preserves bone cell viability [45]. Hormones, estrogens, and androgens inhibit apoptosis in osteoblasts and osteocytes. Also, 1,25-dihydroxyvitamin D3 has anti-apoptotic effects on osteoblasts. Additionally, PTH and PTH-related protein (PTHrP) have the similar effects on cultured osteoblasts of rat, murine, and human via inactivation of Bad, enhanced transcription of survival genes such as Bcl-2, and cAMP-activated protein kinase A [18]. Not surprisingly, some natural compounds have therapeutic effects such as reveromycin A (RM-A). This compound, a small natural product with three carboxylic groups isolated from the genus Streptomyces, induces apoptosis in osteoclasts through induction of cytochrome C release and caspase 3 activation [49]. It was shown that puerarin, which is extracted from the root of a wild leguminous creeper with estrogen-like structure, has an anti-apoptotic effect on human osteoblasts by activation of ERK signaling pathway. So, it could be used as a potential drug for osteoporosis treatment [26]. Similarly, vaspin, an adipocytokine isolated from visceral white adipose tissue, prevents apoptosis on the same cells probably via activating the MAPK/ERK signaling pathway [50]. Besides, adrenomedullin (ADM), synthesized and secreted by a variety of cells, enhances the number of osteoblasts and increases bone growth. Recently, it was shown that ADM possess an osteoblastic anti-apoptotic effect through calcitonin gene-related peptide1 (CGRP1) receptor-MEK-ERK pathway [51]. Apelin, a peptide expressed by adipocyte and osteoblast, inhibits apoptosis mediated by serum deprivation in human osteoblasts through APJ/PI-3 kinase/Akt signaling pathway. It should be noted that APJ is an orphan G protein-coupled receptor and apelin is its endogenous ligand. Apelin has a protective role in glucocorticoid-induced apoptosis [52]. As mentioned earlier, glucocorticoids suppress the number of osteoblasts through reducing ERK activation by mitogens. It has been shown that vanadate (a protein tyrosine phosphatase inhibitor) could act as a survival factor since it inhibits apoptosis mediated by glucocorticoids in pre-osteoblasts and osteocytes [37]. There are lines of evidence that taurine, the most plentiful intracellular amino acid in humans, could conserve osteoblast through taurine transporter (TAUT)/ERK pathway. Moreover, the mechanism of the taurine is associated with reduction of mitochondria-dependent pathways that is decreasing the release of cytochrome C [53]. Taken together, estrogen replacement therapy (ERT), different bisphosphonates (e.g., alendronate), the selective estrogen receptor modulator (SERM), raloxifene, calcitonin, sodium fluoride, calcium, and vitamin D could be used as modulators to treat bone diseases. Androgen and estrogen inhibit apoptosis in osteoblasts and osteocytes; thus, estrogenic, androgenic, or even nonsteroidal compounds are considered as potential drugs for osteoporosis treatment [13].

Conclusion

To sum up, bone diseases especially the intolerable ones could be treated in the early stages of the disease via therapeutic factors triggering the anti-apoptotic pathways. Based on preclinical studies, molecular routes encourage us to think about practical target achievements. However, molecular therapies should be used with more care because of their bilateral role in some cases.

Declarations

Acknowledgements

The authors are thankful to the Vice Chancellor of Research, Mashhad University of Medical Sciences, Iran, for the financial support. This article is part of PhD thesis (SM).

Authors’ Affiliations

(1)
Biotechnology Research Center, Mashhad University of Medical Sciences
(2)
Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences
(3)
Medical Genetics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences
(4)
Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences

References

  1. Hughes DE, Boyce BF. Apoptosis in bone physiology and disease. Mol Pathol. 1997;50:132–7.View ArticlePubMed CentralPubMedGoogle Scholar
  2. Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: impact in bone disease. Histol Histopathol. 2004;19:1325–44.PubMedGoogle Scholar
  3. Stains JP, Civitelli R. Gap junctions in skeletal development and function. Biochim Biophys Acta. 2005;1719:69–81.View ArticlePubMedGoogle Scholar
  4. Sims NA, Walsh NC. Intercellular cross-talk among bone cells: new factors and pathways. Curr Osteoporos Rep. 2012;10:109–17.View ArticlePubMedGoogle Scholar
  5. Watkins M, Grimston SK, Norris JY, Guillotin B, Shaw A, Beniash E, et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell. 2011;22:1240–51.View ArticlePubMed CentralPubMedGoogle Scholar
  6. Loiselle AE, Jiang JX, Donahue HJ. Gap junction and hemichannel function in osteocytes. Bone. 2013;54:205–12.View ArticlePubMedGoogle Scholar
  7. Del Fattore A, Teti A, Rucci N. Bone cells and the mechanisms of bone remodelling. Front Biosci (Elite Ed). 2012;4:2302–21.View ArticleGoogle Scholar
  8. Neve A, Corrado A, Cantatore FP. Osteoblast physiology in normal and pathological conditions. Cell Tissue Res. 2011;343:289–302.View ArticlePubMedGoogle Scholar
  9. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3:S131–9.View ArticlePubMed CentralPubMedGoogle Scholar
  10. Pajevic PD. Regulation of bone resorption and mineral homeostasis by osteocytes. IBMS Bonekey. 2009;6:63–70.View ArticleGoogle Scholar
  11. Rochefort GY, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int. 2010;21:1457–69.View ArticlePubMedGoogle Scholar
  12. Komori T. Functions of the osteocyte network in the regulation of bone mass. Cell Tissue Res. 2013;352:191–8.View ArticlePubMed CentralPubMedGoogle Scholar
  13. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115–37.PubMedGoogle Scholar
  14. Kitaura H, Kimura K, Ishida M, Kohara H, Yoshimatsu M, Takano-Yamamoto T. Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo. Clin Dev Immunol. 2013;2013:181849.View ArticlePubMed CentralPubMedGoogle Scholar
  15. Miyamoto T. Role of osteoclasts in regulating hematopoietic stem and progenitor cells. World J Orthop. 2013;4:198–206.View ArticlePubMed CentralPubMedGoogle Scholar
  16. Väänänen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci. 2000;113:377–81.PubMedGoogle Scholar
  17. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.View ArticlePubMed CentralPubMedGoogle Scholar
  18. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007;22:1492–501.View ArticlePubMedGoogle Scholar
  19. Giner M, Montoya MJ, Vázquez MA, Miranda C, Pérez-Cano R. Differences in osteogenic and apoptotic genes between osteoporotic and osteoarthritic patients. BMC Musculoskelet Disord. 2013;14:41.View ArticlePubMed CentralPubMedGoogle Scholar
  20. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.View ArticlePubMed CentralPubMedGoogle Scholar
  21. MacFarlane M, Williams AC. Apoptosis and disease: a life or death decision. EMBO Rep. 2004;5:674–8.View ArticlePubMed CentralPubMedGoogle Scholar
  22. Rastogi RP, Sinha RP. Apoptosis: molecular mechanism and pathogenicity. EXCLI J. 2009;8:155–81.Google Scholar
  23. Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B, Parent JL. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun. 2005;333:42–50.View ArticlePubMedGoogle Scholar
  24. Almeida M. Aging mechanisms in bone. Bonekey Rep. 2012;1:102.View ArticlePubMed CentralPubMedGoogle Scholar
  25. Miura M, Chen XD, Allen MR, Bi Y, Gronthos S, Seo BM, et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 2004;114:1704–13.View ArticlePubMed CentralPubMedGoogle Scholar
  26. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere MC, et al. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci U S A. 2007;104:2259–64.View ArticlePubMed CentralPubMedGoogle Scholar
  27. Liu LJ, Liu LQ, Bo T, Li SJ, Zhu Z, Cui RR, et al. Puerarin suppress apoptosis of human osteoblasts via ERK signaling pathway. Int J Endocrinol. 2013;2013:786574.PubMed CentralPubMedGoogle Scholar
  28. Izu Y, Sun M, Zwolanek D, Veit G, Williams V, Cha B, et al. Type XII collagen regulates osteoblast polarity and communication during bone formation. J Cell Biol. 2011;193:1115–30.View ArticlePubMed CentralPubMedGoogle Scholar
  29. Plotkin LI, Mathov I, Aguirre JI, Parfitt AM, Manolagas SC, Bellido T. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol. 2005;289:C633–43.View ArticlePubMedGoogle Scholar
  30. Roux S, Brown JP. Osteoclast apoptosis in rheumatic diseases characterized by a high level of bone resorption (osteoporosis, rheumatoid arthritis, myeloma and Paget’s disease of bone). Curr Rheumatol Rev. 2009;5:98–110.View ArticleGoogle Scholar
  31. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907–12.PubMedGoogle Scholar
  32. Calder JD, Buttery L, Revell PA, Pearse M, Polak JM. Apoptosis–a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg (Br). 2004;86:1209–13.View ArticleGoogle Scholar
  33. Kerachian MA, Harvey EJ, Cournoyer D, Chow TY, Séguin C. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium. 2006;13:237–44.View ArticlePubMedGoogle Scholar
  34. Kerachian MA, Cournoyer D, Harvey EJ, Chow TY, Bégin LR, Nahal A, et al. New insights into the pathogenesis of glucocorticoid-induced avascular necrosis: microarray analysis of gene expression in a rat model. Arthritis Res Ther. 2010;12:R124.View ArticlePubMedGoogle Scholar
  35. Kerachian MA, Séguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009;114:121–8.View ArticlePubMedGoogle Scholar
  36. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183–90.View ArticlePubMed CentralPubMedGoogle Scholar
  37. Conradie MM, de Wet H, Kotze DD, Burrin JM, Hough FS, Hulley PA. Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo. J Endocrinol. 2007;195:229–40.View ArticlePubMed CentralPubMedGoogle Scholar
  38. Civitelli R. Connexin43 modulation of osteoblast/osteocyte apoptosis: a potential therapeutic target? J Bone Miner Res. 2008;23:1709–11.View ArticlePubMed CentralPubMedGoogle Scholar
  39. Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol. 2004;126:475–86.View ArticlePubMedGoogle Scholar
  40. Gulce Iz S, Çalimlioglu B, Deliloglu Gurhan SI: Using Bcl-xL anti-apoptotic protein for altering target cell apoptosis. Electron J Biotechnol 2012, 5(5). doi:10.2225/vol15-issue5-fulltext-2.Google Scholar
  41. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol. 1998;10:262–7.View ArticlePubMedGoogle Scholar
  42. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci. 2004;13:1979–87.View ArticlePubMed CentralPubMedGoogle Scholar
  43. Boyce BF, Xing L, Jilka RL, Bellido T, Weinstein RS, Parfitt AM, et al. Apoptosis in bone cells. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. 1st ed. San Diego, CA: Academic Press; 2002. p. 151–68.View ArticleGoogle Scholar
  44. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem. 2009;284:575–84.View ArticlePubMedGoogle Scholar
  45. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008;23:1712–21.View ArticlePubMed CentralPubMedGoogle Scholar
  46. Civitelli R. Cell-cell communication in the osteoblast/osteocyte lineage. Arch Biochem Biophys. 2008;473:188–92.View ArticlePubMed CentralPubMedGoogle Scholar
  47. Lezcano V, Bellido T, Plotkin LI, Boland R, Morelli S. Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate. Exp Cell Res. 2014;324:30–9.View ArticlePubMed CentralPubMedGoogle Scholar
  48. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011;49:50–5.View ArticlePubMed CentralPubMedGoogle Scholar
  49. Woo JT, Kawatani M, Kato M, Shinki T, Yonezawa T, Kanoh N, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006;103:4729–34.View ArticlePubMed CentralPubMedGoogle Scholar
  50. Zhu X, Jiang Y, Shan PF, Shen J, Liang QH, Cui RR, et al. Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway. Amino Acids. 2013;44:961–8.View ArticlePubMedGoogle Scholar
  51. Uzan B, Villemin A, Garel JM, Cressent M. Adrenomedullin is anti-apoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway. J Cell Physiol. 2008;215:122–8.View ArticlePubMedGoogle Scholar
  52. Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Guo LJ, et al. Apelin suppresses apoptosis of human osteoblasts. Apoptosis. 2007;12:247–54.View ArticlePubMedGoogle Scholar
  53. Zhang LY, Zhou YY, Chen F, Wang B, Li J, Deng YW, et al. Taurine inhibits serum deprivation-induced osteoblast apoptosis via the taurine transporter/ERK signaling pathway. Braz J Med Biol Res. 2011;44:618–23.PubMedGoogle Scholar

Copyright

© Mollazadeh et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement